about
Kindlin-2 is required for myocyte elongation and is essential for myogenesisEnvironmental risk factors and amyotrophic lateral sclerosis (ALS): a case-control study of ALS in MichiganSUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycleInsulin-like growth factor-I for the treatment of amyotrophic lateral sclerosisDiabetic neuropathy: one disease or two?Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndromePhenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of the EASD (Neurodiab)Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathyDietary Reversal Ameliorates Short- and Long-Term Memory Deficits Induced by High-fat Diet Early in LifeHuman neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantationRecent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral SclerosisAssociation of Environmental Toxins With Amyotrophic Lateral SclerosisNew Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain.Zebrafish MTMR14 is required for excitation-contraction coupling, developmental motor function and the regulation of autophagy.25 years of neuroimaging in amyotrophic lateral sclerosis.PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal modelsDiabetic neuropathy: mechanisms to managementThe management of diabetic neuropathy in CKD.Diabetes regulates mitochondrial biogenesis and fission in mouse neurons.Integrated systems pharmacology analysis of clinical drug-induced peripheral neuropathy.Dietary reversal of neuropathy in a murine model of prediabetes and metabolic syndrome.Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction.Clinical Trials of Therapies for Amyotrophic Lateral Sclerosis: One Size Does Not Fit AllZebrafish models of collagen VI-related myopathiesp38 mediates mechanical allodynia in a mouse model of type 2 diabetes.Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic miceOntology-based Brucella vaccine literature indexing and systematic analysis of gene-vaccine association network.Accelerated neuritogenesis and maturation of primary spinal motor neurons in response to nanofibers.The design of electrospun PLLA nanofiber scaffolds compatible with serum-free growth of primary motor and sensory neuronsThe effects of anesthesia on measures of nerve conduction velocity in male C57Bl6/J mice.Loss of Miro1-directed mitochondrial movement results in a novel murine model for neuron disease.How neurologists can choose (even more) wisely: prioritizing waste reduction targets and identifying gaps in knowledge.Insulin-like growth factor-I in muscle metabolism and myotherapies.Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials.Multimodal MRI as a diagnostic biomarker for amyotrophic lateral sclerosisNeuroprotection using gene therapy to induce vascular endothelial growth factor-A expressionConcise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the futureMechanisms of disease: the oxidative stress theory of diabetic neuropathyHyperglycemia- and neuropathy-induced changes in mitochondria within sensory nerves.Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study.
P50
Q21284153-84A54125-2039-44F5-AD4D-00BFC367E5D5Q23924099-16EC2B76-AA79-43CA-9C38-E7AEA13BDD72Q24318317-D716FBF3-70C9-4EE2-ACFE-385C05F1FA7BQ24630353-2243D25B-02F3-4242-9D3F-80CE602EC31FQ26859955-35F4B3E6-D4DD-41FD-A550-F760F2EB0453Q27008997-657616FA-2A8B-4C07-A4EF-A39FAF403F7DQ27025404-2D179325-AD18-4618-A1EF-2165E4D239E9Q27313067-DAA0C1A3-7C7F-4895-A5DF-1BABB308012AQ27321064-4FFA3438-0B65-4217-871D-A444D8515FF4Q27324779-A8AD453E-294D-404D-8E28-C99A72DC2150Q27338320-ED22BAB5-C206-4E4A-B77A-90AA42F2B260Q28389852-F3DDEAAF-B58B-46AD-A738-E0F862214A36Q30235132-84A7283C-188B-4272-A8C9-79A4D9CAB53EQ30494835-584CEE96-1344-42D9-8E2F-7715E68D6367Q30659482-03CDC6A6-B3BF-492E-BE93-6EE3D4904461Q30805305-6D621C24-26BE-47AB-8628-895CEA9BABA5Q33554384-E9D8BD43-DEE3-42F6-9EEE-D517F8D5A03AQ33554396-EFF4E390-19DE-4BDF-AB8F-C6EF619D81CEQ33571558-3CC6AB39-B235-4234-9686-979C3A794070Q33733061-1A1C1D7E-A824-4A81-85F5-CEE341AE3F04Q33830497-0BCB7272-3E43-457F-8A7D-8AD48B97CE40Q33862382-CE4095A1-B690-4916-A895-8057C602F462Q33877968-CC11A5B0-A74F-42DA-9D7F-1D91E1156ED0Q33878282-ECD51EF8-B12E-4B3E-BC6D-20905895B2E5Q33895067-AE238F72-7977-49F7-9A94-1276B57D8D07Q33933352-FC1EC6D5-887A-4A8B-82E1-671E9D6F0EC7Q34003852-6A145C91-B7CB-4EB7-809F-D18AFAD5D353Q34037578-EC6CFB93-D30E-4A50-9BC7-F3E7016D0A72Q34070574-9A1F25D3-841B-441F-8665-A986DCF91D7BQ34135732-9B2FC553-EAB5-47C1-859F-90ADB943FC90Q34144429-434D1507-C6F8-4120-A60F-9F5D22319F73Q34157732-9B19BA38-52AC-49F3-AFC4-51978DE19F00Q34329895-42792699-3825-4008-96F7-EE5C4546DB48Q34398786-BAB0B9AC-61AC-43E2-8F80-D8880BF9CC29Q34418793-24D3DBB4-F3C8-4A6F-9ADE-8E3F4E2ECF95Q34430669-A4194F7B-53B4-4224-98F4-68CA0B843468Q34478634-045334B0-1E50-486C-A49E-BE1A6DC9347CQ34553052-81DB2F55-4658-4052-BCA6-51B96421B48FQ34562861-9B570294-3529-424D-BA45-49E7F7D1E3F0Q34583297-1A9A753D-C41B-4A53-ACFF-F8DC044ACB11
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Eva L Feldman
@ast
Eva L Feldman
@en
Eva L Feldman
@es
Eva L Feldman
@nl
type
label
Eva L Feldman
@ast
Eva L Feldman
@en
Eva L Feldman
@es
Eva L Feldman
@nl
prefLabel
Eva L Feldman
@ast
Eva L Feldman
@en
Eva L Feldman
@es
Eva L Feldman
@nl
P31
P496
0000-0002-9162-2694